

toes of all four legs were used for drug evaluation. A test compound was injected intramuscularly (0.05 mL, dose volume) into the thigh in one hind leg, in the region of the sciatic nerve. The vehicle (aqueous 0.5%, w/v, methylcellulose solution, containing 0.4%, w/v, Tween-80) was administered to a separate group of mice. Mice were individually placed on the wire-mesh screen after being treated with test substances. Animals were tested at several time periods after drug administration, and the number of animals that were not able to grasp the screen with the toes of the injected leg (the local anesthetic response) was recorded. Each compound was administered as the HCl salt, and doses were calculated as the active moieties.

Registry No. 1, 114604-40-9; 1·3HCl, 114604-54-5; 2, 114604-41-0; 2·3HCl, 114604-55-6; 3, 114604-43-2; 3·3HCl, 114604-57-8; 4, 114604-59-0; 4·HCl, 115406-99-0; 5, 114604-42-1; 5·2HCl, 114604-56-7; 6, 114604-47-6; 6·3HCl, 114604-62-5; 7, 114604-49-8; 7·3HCl, 114604-64-7; 8, 114604-51-2; 8·2HCl, 114604-66-9; 9, 114604-52-3; 9·3HCl, 114621-58-8; 10, 114604-53-4; 10·3HCl, 114604-67-0; 11, 115407-33-5; 11·2HCl, 115407-47-1; 12, 115407-34-6; 12·2HCl, 115407-48-2; 13, 115407-35-7; 13·2HCl, 115407-49-3; 14, 115407-36-8; 14·2HCl, 115407-50-6; 15, 115407-37-9; 15·HCl, 115407-51-7; 16, 115407-38-0; 16·2HCl, 115407-52-8; 17, 115407-39-1; 17·3HCl, 115407-53-9; 18, 115407-42-6; 18·2HCl, 115407-54-0; 19, 115407-43-7; 19·3HCl, 115407-55-1; 20, 114604-44-3; 20·3HCl, 114604-61-4; 21, 114604-45-4; 21·3HCl, 114604-58-9; 22, 115407-17-5; 22·3HCl, 115407-00-6; 23, 115407-18-6; 23·3HCl, 115407-01-7; 24, 115419-73-3; 24·3HCl, 115407-02-8; 25, 115407-19-7; 25·3HCl, 115407-03-9; 26, 115407-20-0; 26·3HCl, 115407-04-0; 27, 115407-21-1; 27·3HCl, 115407-05-1; 28, 115407-22-2; 28·3HCl, 115407-06-2; 29, 115407-23-3; 29·3HCl, 115407-07-3; 30, 115407-24-4; 30·3HCl, 115407-08-4; 31, 115407-25-5; 31·3HCl, 115407-09-5; 32, 115407-26-6; 32·3HCl, 115407-10-8; 33, 115407-27-7; 33·3HCl, 115407-11-9; 34, 115407-28-8; 34·3HCl, 115407-12-0; 35, 115407-29-9; 35·3HCl, 115407-13-1; VIa, 114604-68-1; VIb, 114604-75-0;

VIc, 115354-34-2; H₃CCH(OH)CO-*p*-C₆H₄O(CH₂)₃Cl, 114604-77-2; H₃CCOCO-*p*-C₆H₄O(CH₂)₃Cl, 115354-33-1; 4-hydroxyacetophenone, 99-93-4; 1-bromo-3-chloropropane, 109-70-6; 4-(3-chloropropoxy)acetophenone, 91427-23-5; 2-amino-3-picoline, 1603-40-3; 2-amino-4-picoline, 695-34-1; 2-amino-3-(benzyloxy)pyridine, 24016-03-3; 2-amino-5-bromopyridine, 1072-97-5; 2-amino-1,3-thiazole, 96-50-4; 2-amino-5-methyl-1,3,4-thiadiazole, 108-33-8; 2-amino-1,3-benzothiazole, 136-95-8; 3-amino-1,2,4-triazine, 1120-99-6; 2-amino-1,3-pyrimidine, 109-12-6; 2-amino-6-methyl-1,3-pyrimidine, 108-52-1; 2-[4-(chloropropoxy)phenyl]-8-methylimidazo[1,2-*a*]pyridine, 114604-70-5; 2-[4-(chloropropoxy)phenyl]-7-methylimidazo[1,2-*a*]pyridine, 114604-72-7; 2-[4-(chloropropoxy)phenyl]-7-(benzyloxy)imidazo[1,2-*a*]pyridine, 114604-74-9; 6-bromo-2-[4-(chloropropoxy)phenyl]imidazo[1,2-*a*]pyridine, 114604-71-6; 6-[4-(chloropropoxy)phenyl]imidazo[2,1-*b*]thiazole, 115407-44-8; 6-[4-(chloropropoxy)phenyl]-2-methylimidazo[2,1-*b*]-1,3,4-thiadiazole, 115407-45-9; 2-[4-(chloropropoxy)phenyl]imidazo[2,1-*b*]benzothiazole, 115407-46-0; 6-[4-(chloropropoxy)phenyl]imidazo[1,2-*b*]triazine, 115407-30-2; 2-[4-(chloropropoxy)phenyl]imidazo[1,2-*a*]pyrimidine, 115407-31-3; 2-[4-(chloropropoxy)phenyl]-7-methylimidazo[1,2-*a*]pyrimidine, 115407-32-4; 2-aminopyridine, 504-29-0; 2-[4-(chloropropoxy)phenyl]imidazo[1,2-*a*]pyridine, 114604-69-2; dibutylamine, 111-92-2; 2-[4-(chloropropoxy)benzoyl]-8-methylimidazo[1,2-*a*]pyridine, 114604-80-7; 2-[4-(chloropropoxy)benzoyl]-7-methylimidazo[1,2-*a*]pyridine, 115407-14-2; 6-bromo-2-[4-(chloropropoxy)benzoyl]imidazo[1,2-*a*]pyridine, 115407-15-3; *N,N*-dimethyl-*N'*-(3-methylpyridyl)-formamide, 36172-55-1; *N,N*-dimethyl-*N'*-pyrimidylformamide, 6578-34-3; α -bromo-4-hydroxyacetophenone, 2491-38-5; 3-(4-hydroxybenzoyl)-8-methylimidazo[1,2-*a*]pyridine, 114604-81-8; 3-(4-hydroxybenzoyl)imidazo[1,2-*a*]pyrimidine, 115407-40-4; 3-(dibutylamino)propyl chloride, 36421-15-5; 6-bromo-3-(4-hydroxybenzoyl)imidazo[1,2-*a*]pyridine, 115407-16-4; 3-(4-hydroxybenzoyl)-7-methylimidazo[1,2-*a*]pyrimidine, 115407-41-5.

Additions and Corrections

1988, Volume 31

David B. Kanne* and **Leo G. Abood**: Synthesis and Biological Characterization of Pyridohomotropans. Structure-Activity Relationships of Conformationally Restricted Nicotinoids.

Page 506. The tropane derived name for structure **3a** should read "pyrido[3,4-*b*]norhomotropane" (instead of "pyrido[3,4-*b*]homotropane"). The correct tropane derived names for **3b** and **3c** are "2'-methylpyrido[3,4-*b*]norhomotropane" and "pyrido[3,4-*b*]homotropane", respectively.

Andre Rosowsky,* Henry Bader, William Kohler, James H. Freisheim, and Richard G. Moran: Methotrexate Analogues. 34. Replacement of the Glutamate Moiety in Methotrexate and Aminopterin by Long-Chain 2-Aminoalkanedioic Acids.

Page 1344. The registry numbers for compounds **21-24** should be as follows: **21**, 95485-01-1; **22**, 113976-36-6; **23**, 113976-37-7; **24**, 113976-38-8.

James Burton,* Stephen G. Wood, Mary Lynch, and Andrew G. Plaut: Substrate Analogue Inhibitors of the IgA1 Proteinases from *Neisseria gonorrhoeae*.

Page 1651. Corrected registry numbers are as follows: HRP-18 (tritium labeled), 116099-30-0; HRP-19 (tritium labeled), 116099-31-1; HRP-20 (tritium labeled), 116099-32-2; HRP-21 (tritium labeled), 116099-33-3; HRP-25 (tritium labeled), 116099-29-7; HRP-59 (tritium labeled), 114819-68-0; HRP-61 (tritium labeled), 114819-70-4; HRP-62 (tritium labeled), 114791-18-3; HRP-63 (tritium labeled), 114791-19-4; HRP-64 (tritium labeled), 114791-20-7.